GlaxoSmithKline | GSK - Loan Capital



GlaxoSmithKline reported GBP15.3B in Loan Capital for its fiscal quarter ending in June of 2025.


Loan Capital Change Date
AbbVie USD 64.53B 4.19B Mar/2025
Alcon AG USD 4.66B 68M Jun/2025
Almirall EUR 365.88M 24.38M Jun/2025
Amgen USD 53.76B 253M Jun/2025
argenx SE 35.57M 32.76M Jun/2025
AstraZeneca USD 25.99B 1.9B Jun/2025
Bayer EUR 31.71B 3.31B Jun/2025
Biogen USD 6.28B 1.74B Jun/2025
Bristol-Myers Squibb USD 44.47B 1.69B Jun/2025
Eli Lilly USD 34.18B 319.4M Jun/2025
Fresenius EUR 9.31B 2.08B Jun/2025
Fresenius Medical Care EUR 6.33B 3.18B Jun/2025
Galapagos EUR 6.05M 1.74M Jun/2025
Genmab DKK 132M 3M Jun/2025
Gilead Sciences USD 22.14B 6M Jun/2025
GlaxoSmithKline GBP 15.3B 1.17B Jun/2025
Glaxosmithkline GBP 15.3B 667M Jun/2025
GRIFOLS EUR 7.45B 1.94B Jun/2025
Hikma Pharmaceutical USD 607M 454M Dec/2024
Lonza CHF 4.24B 602M Dec/2024
Merck EUR 6.3B 665M Jun/2025
Merck USD 33.97B 484M Jun/2025
Novartis USD 24.06B 2.4B Jun/2025
Novo Nordisk 87.3B 9.01B Jun/2025
Orion EUR 136M 154.8M Jun/2025
Pfizer USD 57.5B 137M Jun/2025
Philips EUR 7.18B 126M Jun/2025
Recordati EUR 2.09B 37.29M Jun/2025
Regeneron Pharmaceuticals USD 1.99B 719.7M Jun/2025
Roche Holding CHF 32.1B 1.94B Dec/2024
Sanofi 13.2B 211M Jun/2025
Smith & Nephew USD 3.3B 39M Jun/2025
UCB EUR 2.96B 21M Dec/2024